Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 11;25(1):1426–1437. doi: 10.1080/10717544.2018.1474970

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 6. — The in vivo kinetic, distribution characteristics, anticancer effects, and safety of EA and EFEN. (a) Plasma EA concentration versus time profiles; (b) pharmacokinetic parameters of EA and EFEN. The data were shown as mean ± SD. n = 6 rats per group. *p ＜ .05 indicated significant differences between EA and EFEN; (c) accumulation of EFEN at the tumor site after administration; (d) effects of EFEN on cancer sizes and weight, *p ＜ .05 indicated significant differences between the sample group and the control group, $P < .05 indicated significant differences between the sample group and Blank EFEN group, & P ＜.05 indicated significant differences between the sample group and EA; (e) stimulation; and (f) hemolytic evaluations of EFEN. Normal saline solution was used as the negative control in stimulation and hemolytic tests.